KA Alexander, L Raggatt, M Chang… - … Society of Bone …, 2011 - espace.library.uq.edu.au Osteal tissues contain a resident population of macrophages (osteomacs) and in vitro these cells regulate osteoblast mineralisation. In vivo osteomacs form a canopy structure covering osteoblast bone forming surfaces (ObS) and depletion of osteomacs, using the Macrophage-Fas- ... Cited by 1 - Related articles - Cached - All 4 versions
JA Eisman, HG Bone, DJ Hosking… - Journal of Bone and …, 2011 - Wiley Online Library Page 1. Original Article Odanacatib in the Treatment of Postmenopausal Women with Low Bone Mineral Density: Three-year Continued Therapy and Resolution of Effect John A. Eisman MBBS, Ph.D.1, Henry G. Bone, MD2, David J. Hosking, MD3, ... Cited by 15 - Related articles - All 3 versions
HG Bone, MA Bolognese, CK Yuen… - Journal of Clinical …, 2011 - Endocrine Soc Context: Denosumab treatment for 24 months increased bone mineral density (BMD) and reduced bone turnover markers (BTM) in postmenopausal women. ... Objective: The aim was to determine the effects of prior denosumab or placebo injections on BMD, BTM, and safety over 24 ... Cited by 8 - Related articles - All 3 versions
B Bragdon, S Thinakaran, O Moseychuk, L Gurski… - Bone, 2011 - Elsevier We previously identified Protein Kinase CK2 to interact with BMP receptor type Ia (BMPRIa) and as a key protein for signal activation. Peptides approximately 30 AA were developed that mimicked BMP2 action in vitro by blocking this interaction. In this paper we extended our studies to ...
[PDF] from ued-ham.org.br…, DN Gordon, S Papapoulos, HG Bone… - Journal of Clinical …, 2011 - Endocrine Soc Page 1. The Effects of Ronacaleret, a Calcium-Sensing Receptor Antagonist, on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women with Low Bone Mineral Density Lorraine A. Fitzpatrick ... Cited by 1 - Related articles - All 3 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
